Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?

ABSTRACT:

Purpose of review

Anti-nerve growth factor (NGF) antibodies hold tremendous potential for the management of osteoarthritis pain, but clinical trials have revealed serious adverse effects that are incompletely understood. This review discusses clinical trial results along with preclinical studies that have assessed NGF blockade in experimental osteoarthritis, in order to provide insight for future studies.

Recent findings

Systematic reviews have revealed that anti-NGF therapy, including tanezumab, is efficacious in improving pain and function, but serious adverse events, including rapidly progressive osteoarthritis and osteonecrosis, resulted in a moratorium on trials that was only recently lifted. Within the past year, preclinical testing has revealed effects of NGF blockade

SUBMITTER: Miller RE 

PROVIDER: S-EPMC5436144 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature